Skip to main content
Journal cover image

How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?

Publication ,  Journal Article
Zaki, IH; Shropshire, E; Zhang, S; Xiao, D; Wildman-Tobriner, B; Marin, D; Gupta, RT; Erkanli, A; Nelson, RC; Bashir, MR
Published in: Abdom Radiol (NY)
March 2021

OBJECTIVE: To determine the rate of development of clinically significant liver nodules (LR-4, LR-5, LR-M) after a negative MRI in an HCC screening population. METHODS: This retrospective study included patients at risk of developing HCC requiring imaging surveillance who had undergone multiphase Gadobenate dimeglumine-enhanced MRI that was negative and had follow up LI-RADS compliant multiphase CTs or MRIs for at least 12 months or positive follow-up within 12 months. Follow-up examinations were classified as negative (no nodules or only LR-1 nodules) or positive (nodule other than LR-1). Time-to-first positive examination, types of nodules, and cumulative incidence of nodule development were recorded. RESULTS: 204 patients (mean age 58.9 ± 10.2 years, 128 women), including 172 with cirrhosis, were included. Based CT/MRI follow-up (median 35 months, range 12-80 months), the overall cumulative incidence of developing a nodule was 10.5%. Cumulative incidence of nodule development was: 0.5% at 6-9 months and 2.1% at 12 ± 3 months, including one LR-4 nodule, one LR-M nodule, and two LR-3 nodules. The cumulative incidence of clinically significant nodule development was 1.1% at 9-15 months. 70% (143/204) of patients also underwent at least one US follow-up, and no patient developed a positive US examination following index negative MRI. CONCLUSION: Clinically significant liver nodules develop in 1.1% of at-risk patients in the first year following negative MRI. While ongoing surveillance is necessary for at-risk patients, our study suggests than longer surveillance intervals after a negative MRI may be reasonable and that further research is needed to explore this possibility.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Abdom Radiol (NY)

DOI

EISSN

2366-0058

Publication Date

March 2021

Volume

46

Issue

3

Start / End Page

969 / 978

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Organometallic Compounds
  • Middle Aged
  • Meglumine
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans
  • Female
  • Carcinoma, Hepatocellular
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zaki, I. H., Shropshire, E., Zhang, S., Xiao, D., Wildman-Tobriner, B., Marin, D., … Bashir, M. R. (2021). How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY), 46(3), 969–978. https://doi.org/10.1007/s00261-020-02771-5
Zaki, Islam H., Erin Shropshire, Shuaiqi Zhang, Dong Xiao, Benjamin Wildman-Tobriner, Daniele Marin, Rajan T. Gupta, Alaattin Erkanli, Redon C. Nelson, and Mustafa R. Bashir. “How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?Abdom Radiol (NY) 46, no. 3 (March 2021): 969–78. https://doi.org/10.1007/s00261-020-02771-5.
Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, et al. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY). 2021 Mar;46(3):969–78.
Zaki, Islam H., et al. “How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?Abdom Radiol (NY), vol. 46, no. 3, Mar. 2021, pp. 969–78. Pubmed, doi:10.1007/s00261-020-02771-5.
Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY). 2021 Mar;46(3):969–978.
Journal cover image

Published In

Abdom Radiol (NY)

DOI

EISSN

2366-0058

Publication Date

March 2021

Volume

46

Issue

3

Start / End Page

969 / 978

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Organometallic Compounds
  • Middle Aged
  • Meglumine
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans
  • Female
  • Carcinoma, Hepatocellular
  • Aged